Case Summary:

Our client, a Staff Scientist from China, approached North America Immigration Law Group (NAILG) to file an I-140 petition under the EB-2 NIW category. His petition demonstrated his critical research contributions toward developing novel anticancer therapeutics derived from microorganisms, specifically through integrated applications of genome mining, biosynthetic engineering, and synthetic biology. With compelling evidence of influence and innovation, we successfully secured the petition’s approval without a Request for Evidence (RFE).

Engineering Therapeutic Compounds from Microbial Genomes

The client’s research focuses on discovering and optimizing microbial compounds for pharmaceutical applications. These agents show exceptional promise in cancer treatment due to their potent bioactivity and lower toxicity profiles. Through bioengineering and genome exploration, he identifies novel pathways and enzymes to generate analogs that improve drug efficacy and scalability.

His work addresses significant challenges in the pharmaceutical industry and directly supports public health priorities and national innovation in drug discovery.

A Recognized Leader in Natural Product Discovery

● 20 peer-reviewed publications, with 5 as first author and 5 as co–first author
● Over 410 citations across chemical biology and pharmaceutical sciences
● 14 confirmed peer reviews for high-impact journals
● 7 papers ranked among the top 20 %–1 % most cited in their field and publication year

His research has been featured in premier journals such as Nature Chemical Biology, Journal of the American Chemical Society, and PNAS, highlighting both the originality and influence of his scientific output.

He has even received 2 letters of recommendation from fellow experts, one of whom stated:

“[Client] has directly benefited the United States healthcare system through his work on optimising mammography and healthcare efficiency. His innovative algorithms for cancer detection and healthcare benchmarking are beneficial as they improve early breast cancer diagnosis, facilitate better patient outcomes, and reduce healthcare costs.”

These efforts have already led to several widely cited publications and influenced the direction of numerous independent research projects worldwide.

NAILG’s Legal Strategy: Aligning Science with National Interest

Our petition emphasized the alignment of the client’s research with U.S. critical and emerging technologies, as outlined by federal agencies. We argued that:

● His endeavor held substantial merit and national importance in advancing cancer therapies
● He was well-positioned based on his research track record and expert recognition
● A waiver of the job offer requirement would benefit the United States, enabling continued innovation without constraint

The case was approved swiftly, a reflection of both the strength of the case and USCIS’s recognition of the significance of his work.